Italy’s Angelini invests up to $506 million in Japan’s JCR for epilepsy drug
ROME (Reuters) -Family-owned Italian industrial conglomerate Angelini is set to invest up to $505.5 million to fund development of a new treatment for epilepsy by Japan’s JCR Pharmaceuticals, capable of penetrating the blood-brain barrier. JCR owns a blood-brain barrier technology, dubbed J-Brain Cargo, which allows biotherapeutics to reach the central nervous system via a mechanism …
Italy’s Angelini invests up to $506 million in Japan’s JCR for epilepsy drug Read More »